Jacobio Pharmaceuticals
在场
Jacobio Pharmaceuticals 是一家在股票代码 1167 (HK) 下上市的公司。
高管
查看带有其 21 名主要高管的组织结构图
Jacobio Pharmaceuticals 搜索最多的简介
- Yinxiang Wang, Chief Executive Officer and Chairman of the Board
- Bai Lu, Independent Non-executive Director
- Song Ruilin, Non-Executive Director
创建提醒
跟踪 Jacobio Pharmaceuticals 的高管变动
药店
Jacobio Pharmaceuticals 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Jacobio Pharmaceuticals 的最新新闻稿
- Jacobio Pharma Completes First Patient Dosage of Pan-KRAS Inhibitor | Jacobio Pharma
- Glecirasib Pancreatic Cancer Indication Received Orphan Drug Designation from EMA | Jacobio Pharma
- Jacobio Presents Pre-clinical Data of SHP2 plus KRAS G12C | Jacobio Pharma
- Jacobio Pharma to Present BET Inhibitor Data at 2024 ASH | Jacobio Pharma
- Jacobio Received RMB 172 million Payment | Jacobio Pharma
- Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from China CDE | Jacobio Pharma
- Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from FDA | Jacobio Pharma
- Jacobio Pharma Presents Efficacy Data of Glecirasib in Combination with JAB-3312 with PD-L1 Expression Levels | Jacobio Pharma
- Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China | Jacobio Pharma
- Company News | Jacobio Pharma
- View more press releases Close
通过电子邮件
